Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis pipeline: 7 tracked drugs, 3 approved for this indication.
3 approved / phase 42 Phase 32 preclinical / unstaged
Compare the share prices of listed companies in Idiopathic Pulmonary Fibrosis →
Total attributable cost
$6.5B
$41,652/patient
Drug spend
$3.3B
$21,067/patient
any · US